New aspects in health economic studies of prevention and treatment of osteoporosis

References

• Sanders KM, Nicholson GC, Ugoni AM, Pasco JA, Seeman E, Kotowicz MA. Health burden of hip and other fractures in Australia beyond 2000. Projections based on the Geelong Osteoporosis Study. Med. J. Aus. 170, 467–470 (1999).
   Google Scholar
• Parkkari J, Kannus P, Niemi S Increasing age-adjusted incidence of hip fractures in Finland: the number and incidence of fractures in 1970-1991 and prediction for the future. Calcif Tissue Int. 55, 342–345 (1994).
   PubMedGoogle Scholar
• Walker-Bone K, Dennison E, Cooper C.Epidemiology of osteoporosis. Rheum. Dis. Clin. North Arn. 27, 1–18 (2001).
   PubMed Web of Science ®Google Scholar
• Dennison E, Cooper C. Epidemiology of osteoporotic fractures. Holm. Res. 54\(Suppl. 1), 58–63 (2000).
   Google Scholar
• Martyn CN, Cooper C. Prediction of burden of hip fracture. Lancet 353, 769–770 (1999).
   PubMedGoogle Scholar
• Kannus P, Parkkari J, Sievanen H, Heinonen A, Vuori I, Jarvinen M. Epidemiology of hip fractures. Bone 18, 57S-63S (1996).
   Google Scholar
• Sendi P, Palmer AJ. Modeling the socioeconomic impact of osteoporosis-related hip fractures in Switzerland. Osteoporos. Int. 11, 92–94 (2000) .
   PubMedGoogle Scholar
• Koeck CM, Schwappach DL, Niemann FM, Strassmann TJ, Ebner H, Klaushofer K. Incidence and costs of osteoporosis-associated hip fractures in Austria. Wien Wochenschr 113, 371–377 (2001).
   PubMed Web of Science ®Google Scholar
• Wiktorowicz ME, Goeree R, Papaioannou A, Adachi JD, Papadimitropoulos E. Economic implications of hip fracture: health service use, institutional care and cost in Canada. Osteoporos. Int. 12, 271–278 (2001).
   Google Scholar
• Johansen A, Stone M. The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporos. Int. 11, 551–552 (2000).
   PubMed Web of Science ®Google Scholar
• Hoerger TJ, Downs KE, Lakshmanan MC et al. Healthcare use among US women aged 45 and older: total costs and costs for selected postmenopausal health risks. J.Womens Health Cenci. Bared Med. 8, 1077–1089 (1999).
   Google Scholar
• Manson JE. Postmenopausal hormone therapy and atherosclerotic disease. Am. Heart.j 128, 1337–1343 (1994).
   PubMed Web of Science ®Google Scholar
• Nair GV, Klein KP, Herrington DM.Assessing the role of oestrogen in the prevention of cardiovascular disease. Ann. Med. 33, 305–312 (2001).
   Google Scholar
• Manson JE, Martin KA. Clinical practice. Postmenopausal hormone-replacement therapy. N. Engl. Med 345, 34–40 (2001). This article outlines the pro's and con's of HRT.
   Google Scholar
• Matthews IKA, Kuller LH, Wing RR, Meilahn EN, Plantinga P Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J. Epidemiol. 143, 971–978 (1996).
   Google Scholar
• Blakely JA. The heart and estrogen/progestin replacement study revisited: hormone replacement therapy produced net harm, consistent with the observational data. Arch. Intern. Med 160, 2897–2900 (2000). This article outlines the pro's and con's of HRT and secondary CVD prevention.
   Google Scholar
• Hulley S, Grady D, Bush T Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAIVIA 280, 605–613 (1998).
   Google Scholar
• Hemminki E, McPherson K. Impact ofpostmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. BE Med. J. 315, 149–153 (1997).
   Google Scholar
• Simon JA, Hsia J, Cauley JA . Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen-progestin Replacement Study (HERS). Circulation 103, 638–642 (2001).
   PubMed Web of Science ®Google Scholar
• Mosca L, Collins P, Herrington D . Hormone Replacement Therapy and Cardiovascular Disease. A Statement for Healthcare Professionals From the American Heart Association. Circulation 104, 499–503 (2001).Updates the official position with regard to HRT and CVD prevention in light of recent findings.
   Google Scholar
• Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 350, 1047–1059 (1997).
   Google Scholar
• Grady D, Wenger NK, Herrington D . Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann. Intern. Merl 132, 689–696 (2000).
   Google Scholar
• Castellsague J, Perez GS, Garcia RodriguezLA. Recent epidemiological studies of the association between hormone replacement therapy and venous thromboembolism. A review. Drug • Sal 18, 117–123 (1998).
   Google Scholar
• Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAIVIA 285, 2891–2897 (2001).
   PubMed Web of Science ®Google Scholar
• Hulley S, Grady D, Bush T Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAIVIA 280, 605–613 (1998).
   Google Scholar
• Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann. Intern Merl 122, 9–16 (1995).
   PubMed Web of Science ®Google Scholar
• Michaelsson K, Baron JA, Farahmand BY et al Hormone replacement therapy and risk of hip fracture: population based case-control study. The Swedish Hip Fracture Study Group. BrMLj 316, 1858–1863 (1998).
   Google Scholar
• Naessen T, Persson I, Adami HO,Bergstrom R, Bergkvist L. Hormone replacement therapy and the risk for first hip fracture. A prospective, population-based cohort study. Ann. Intern Merl 113, 95–103 (1990).
   Google Scholar
• Cauley JA, Black DM, Barrett-Connor E et al. Effects of hormone replacement therapy on clinical fractures and height loss: The Heart and Estrogen/Progestin Replacement Study (HERS). Ainj Merl 110, 442–450 (2001).
   Google Scholar
• Ettinger B, Black DM, Mitlak BH et alReduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAIVIA 282, 637–645 (1999).
   Google Scholar
• Chesnut CH III, Silverman S, Andriano K etal. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am. J. Med. 109, 267–276 (2000).
   Google Scholar
• Coyle D, Cranney A, Lee KM, Welch V,Tugwell P. Cost effectiveness of nasal calcitonin in postmenopausal women: use of Cochrane collaboration methods for meta-analysis within economic evaluation. PharmacoEconomics 19, 565–575 (2001).
   PubMed Web of Science ®Google Scholar
• Rosner AJ, Grima DT, Torrance GW etal. Cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis. PharmacoEconomics 14, 559–573 (1998).
   Google Scholar
• Tosteson AN, Van Orden LS, Minshall ME etal. Cost-effectiveness of pharmaceutical interventions in postmenopausal women: a comparison of raloxifene, hormone replacement therapy (HRT) and alendronate. J. Bone Miner Res. 14 (Suppl. 1), S398 (1999).
   Google Scholar
• Jonsson B, Kanis J, Dawson A, Oden A, Johnell 0. Health Economic Considerations for the Prevention of Hip Fractures in Postmenopausal Women. J. Bone Miner Res. 14\(Suppl. 1), S203 (1999).
   Google Scholar
• Kanis J, Jonsson B, Dawson A, Oden A,Johnell 0. Cost-Effectiveness of Raloxifene: An Economic Evaluation Based on Swedish Data. J. Bone Miner Res. 14 (Suppl. 1), S389 (1999).
   Google Scholar
• News in brief. Osteoporosis treatment recommended in US. BE Merl J. 323, 300 (2001).
   Google Scholar
• Neer RM, Arnaud CD, Zanchetta JR . Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. Merl 344, 1434–1441 (2001). Clinical trial report of one intervention that is likely to feature strongly in cost-effectiveness analyses in the future.
   Google Scholar
• Bendich A, Leader S, Muhuri P. Supplementalcalcium for the prevention of hip fracture:potential health-economic benefits. Gun. Ther 21, 1058–1072 (1999).
   Google Scholar
• Gillespie WJ, Avenell A, Henry DA,O'Connell DL, Robertson J. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and postmenopausal osteoporosis (Cochrane Review). The Cochrane Library, 3, Oxford, UK: Update Software (2001).
   Google Scholar
• Parker MJ, Gillespie LD, Gillespie WJ. Hip protectors for preventing hip fractures in the elderly (Cochrane Review). Cochrane Database Syst Rev2, CD001255 (2001).
   Google Scholar
• Kumar BA, Parker MJ. Are hip protectors cost effective? Injury 3l, 693–695 (2000).
   Google Scholar
• Tosteson AN, Weinstein MC. Cost-effectiveness of hormone replacement therapy after the menopause. Bailiieres Gun. Obstet. Cynaecol 5, 943–959 (1991).
   PubMedGoogle Scholar
• Jonsson B, Christiansen C, Johnell 0, Hedbrandt J. Cost-effectiveness of fracture prevention in established osteoporosis. Osteoporos. Int. 5, 136–142 (1995).
   Google Scholar
• Jonsson B, Kanis J, Dawson A, Oden A,Johnell 0. Effect and offset of effect of treatment for hip fracture on health outcomes. Osteopoms. Int 10, 193–199 (1999).
   Google Scholar
• Le Pen C, Maurel F, Breart G The long-term effectiveness of preventive strategies for osteoporosis in postmenopausal women: a modeling approach. Osteopoms. Int. 11, 524–532 (2000).
   PubMedGoogle Scholar
• Torgerson DJ, Reid DM. The pharmacoeconomics of hormone replacement therapy. PharmacoEconomics 16,9–16 (1999).
   PubMedGoogle Scholar
• Grodstein F, Manson JE, Stampfer MJ.Postmenopausal hormone use and secondary prevention of coronary events in the nurses' health study. A prospective, observational study. Ann. Intern Merl 135, 1–8 (2001).
   Google Scholar
• Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin. TilaIs 19,61–109 (1998).
   Google Scholar
• Kirchhof B, Palmer AJ, Kakkar VV,Bergemann R. The economic burden of deep vein thrombosis sequelae: a cost of illness analysis for Germany. Cesunclheitsökonomie uncl Qualitatsmanagement2, 40–44 (1997).
   Google Scholar
• Douketis JD, Kearon C, Bates S, Duku EK,Ginsberg JS. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAIVIA 279,458–462 (1998).
   Google Scholar